NPI 1194318600: Open Payments
NPI 1194318600. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,561 in 59 payments from 16 companies in 2025. Trend: 2023 $922 · 2024 $1,388 · 2025 $1,561
Food & beverage: $1,379Education: $182
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 16 | $459 |
| ABBVIE INC. | 6 | $196 |
| Galderma Laboratories, L.P. | 6 | $181 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $116 |
| UCB, Inc. | 4 | $95 |
| Amgen Inc. | 2 | $91 |
| Janssen Biotech, Inc. | 4 | $73 |
| Novartis Pharmaceuticals Corporation | 3 | $62 |
| Organon LLC | 4 | $62 |
| PFIZER INC. | 3 | $55 |
Products named: DUPIXENT, NEMLUVIO, RINVOQ, Bimzelx, TREMFYA, SKYRIZI, ADBRY, CIBINQO.
